OBJECTIVE: To compare compliance and infant HIV-1 infection risk at 6 weeks with the Thai-CDC and HIVNET-012 antiretroviral regimens in a field setting. DESIGN: Randomized clinical trial. SETTING:Tertiary hospital antenatal clinic in Nairobi, Kenya. PARTICIPANTS: HIV-1 infected women referred from primary care clinics. INTERVENTIONS:Thai-CDC zidovudine regimen or HIVNET-012 nevirapine regimen. MAIN OUTCOME MEASURES: Women were considered compliant if they used >or= 80% of the doses. Infants were tested for HIV-1 at 6 weeks. RESULTS Seventy women were randomized to Thai-CDC and 69 to HIVNET-012 regimens. More women were compliant with the antenatal (86%) than the intrapartum (44%) Thai-CDC regimen doses ( P= 0.001). Ninety-seven per cent took the maternal and 91% gave the infant dose of the HIVNET-012 regimen (P = 0.2). Overall, 41% were compliant with the Thai-CDC regimen and 87% with the HIVNET-012 regimen ( P< 0.001). Compliance with the Thai-CDC regimen was associated with partner support of antiretroviral use [odds ratio (OR), 3.0;, 95% confidence interval (CI), 1.0-9.1] and knowledge at recruitment that antiretroviral drugs could prevent infant HIV-1 (OR, 2.9; 95% CI, 1.0-8.1). Compliance with the HIVNET-012 regimen was associated with partner notification (OR, 8.0; 95% CI, 1.5-50) and partner willingness to have HIV-1 testing (OR, 7.5; 95% CI, 1.4-40). There was a trend for a higher risk of transmission with the HIVNET-012 regimen than with the Thai-CDC regimen (22% versus 9%; P= 0.07). CONCLUSION: Compliance with the Thai-CDC and HIVNET-012 regimens was comparable to that in efficacy trials. Partner involvement, support and education on perinatal HIV-1 prevention may improve compliance and increase the number of infants protected from HIV-1 infection.
RCT Entities:
OBJECTIVE: To compare compliance and infantHIV-1 infection risk at 6 weeks with the Thai-CDC and HIVNET-012 antiretroviral regimens in a field setting. DESIGN: Randomized clinical trial. SETTING: Tertiary hospital antenatal clinic in Nairobi, Kenya. PARTICIPANTS: HIV-1 infectedwomen referred from primary care clinics. INTERVENTIONS: Thai-CDC zidovudine regimen or HIVNET-012 nevirapine regimen. MAIN OUTCOME MEASURES: Women were considered compliant if they used >or= 80% of the doses. Infants were tested for HIV-1 at 6 weeks. RESULTS Seventy women were randomized to Thai-CDC and 69 to HIVNET-012 regimens. More women were compliant with the antenatal (86%) than the intrapartum (44%) Thai-CDC regimen doses ( P= 0.001). Ninety-seven per cent took the maternal and 91% gave the infant dose of the HIVNET-012 regimen (P = 0.2). Overall, 41% were compliant with the Thai-CDC regimen and 87% with the HIVNET-012 regimen ( P< 0.001). Compliance with the Thai-CDC regimen was associated with partner support of antiretroviral use [odds ratio (OR), 3.0;, 95% confidence interval (CI), 1.0-9.1] and knowledge at recruitment that antiretroviral drugs could prevent infantHIV-1 (OR, 2.9; 95% CI, 1.0-8.1). Compliance with the HIVNET-012 regimen was associated with partner notification (OR, 8.0; 95% CI, 1.5-50) and partner willingness to have HIV-1 testing (OR, 7.5; 95% CI, 1.4-40). There was a trend for a higher risk of transmission with the HIVNET-012 regimen than with the Thai-CDC regimen (22% versus 9%; P= 0.07). CONCLUSION: Compliance with the Thai-CDC and HIVNET-012 regimens was comparable to that in efficacy trials. Partner involvement, support and education on perinatal HIV-1 prevention may improve compliance and increase the number of infants protected from HIV-1 infection.
Authors: N Shaffer; R Chuachoowong; P A Mock; C Bhadrakom; W Siriwasin; N L Young; T Chotpitayasunondh; S Chearskul; A Roongpisuthipong; P Chinayon; J Karon; T D Mastro; R J Simonds Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: S Z Wiktor; E Ekpini; J M Karon; J Nkengasong; C Maurice; S T Severin; T H Roels; M K Kouassi; E M Lackritz; I M Coulibaly; A E Greenberg Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: Carey Farquhar; James N Kiarie; Barbra A Richardson; Marjory N Kabura; Francis N John; Ruth W Nduati; Dorothy A Mbori-Ngacha; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: Nicole L Davis; William C Miller; Michael G Hudgens; Charles S Chasela; Dorothy Sichali; Dumbani Kayira; Julie A E Nelson; Jeffrey S A Stringer; Sascha R Ellington; Athena P Kourtis; Denise J Jamieson; Charles van der Horst Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: David A Katz; James N Kiarie; Grace C John-Stewart; Barbra A Richardson; Francis N John; Carey Farquhar Journal: PLoS One Date: 2009-11-02 Impact factor: 3.240